Current TMS Clinical Trials: What's Being Studied and How to Participate

TMS research is expanding fast

The FDA has cleared TMS for major depressive disorder, OCD, smoking cessation, and migraine. Four indications. But the technology can do more than that — a lot more.

Right now, hundreds of clinical trials are testing TMS for conditions that affect millions of people who’ve run out of conventional options. Anxiety. PTSD. Chronic pain. Autism. Bipolar depression. The list keeps growing.

If you’re considering TMS for something that isn’t FDA-cleared yet, a clinical trial might be your best path to treatment. Often at no cost. Often with access to protocols you can’t get anywhere else.

Here’s what’s actively being studied and how to get involved.

Active areas of TMS research

Anxiety disorders

Generalized anxiety and social anxiety are among the most studied non-approved TMS indications. Multiple trials are testing high-frequency left DLPFC stimulation, low-frequency right DLPFC protocols, and intermittent theta burst stimulation (iTBS) to shorten session times.

Early data: 40-50% response rates. Good enough that major research centers keep pouring money into bigger studies.

Active trials include studies at UCLA examining accelerated rTMS at frequencies beyond the standard 10 Hz for inpatient MDD with comorbid anxiety (NCT enrolling 30 participants), and UC San Diego leading a 75-participant, three-site trial (with Weill Cornell Medicine and Australian National University) examining whether maintenance rTMS can sustain DLPFC-subgenual cingulate connectivity improvements. Stanford and MUSC are both running multi-site anxiety trials using neuroimaging-guided targeting instead of the standard 5-cm rule — better aim, potentially better results.

PTSD

TMS for PTSD has serious momentum. The VA system is running several large trials across its network. Columbia University’s psychiatry department has been studying deep TMS protocols built to reach the medial prefrontal cortex — the region at the center of fear processing and extinction.

Protocols under investigation include standard rTMS and accelerated approaches modeled on the Stanford Neuromodulation Therapy protocol. Some trials pair TMS with exposure therapy — stimulating the prefrontal cortex right before trauma-focused psychotherapy sessions. The logic is simple: TMS-enhanced prefrontal activity may help the brain process and reconsolidate traumatic memories more effectively.

PTSD trials typically require a formal diagnosis, documented treatment resistance (usually failure of at least one medication and one course of psychotherapy), and stable medication for 4-6 weeks before enrollment.

Autism spectrum disorder

Research on TMS for autism is earlier-stage but generating real interest. Studies at UCLA and Boston Children’s Hospital are exploring whether low-frequency rTMS applied to overactive cortical regions can reduce sensory hypersensitivity and improve social communication in adolescents and adults with ASD.

The hypothesis: many ASD symptoms may stem from too much cortical excitation relative to inhibition (the excitatory/inhibitory imbalance theory). By dampening overactive regions with inhibitory TMS protocols, researchers hope to restore a more typical balance.

Small pilot studies have shown enough promise to justify larger trials. Still early days. But worth watching.

Bipolar depression

This one requires caution. There’s a real risk of triggering mania or hypomania with brain stimulation. Several carefully designed trials are testing modified protocols — lower stimulation intensities, right-sided stimulation, close monitoring — to see whether TMS can help the depressive phase of bipolar disorder without destabilizing mood.

MUSC and Massachusetts General Hospital are leading this work. Their protocols include daily mood monitoring and rapid-response safety plans. That level of care has reassured institutional review boards and allowed the trials to move forward with larger sample sizes than earlier attempts.

Chronic pain

Chronic pain might be one of TMS’s most promising frontiers. UCSF is currently recruiting 20 patients for a randomized, single-blind, crossover pilot trial of TMS for chronic neuropathic pain (NCT05593237). UCLA, Johns Hopkins, and several European centers are also studying motor cortex stimulation for fibromyalgia, neuropathic pain, and chronic migraine prevention.

The mechanism is different from depression treatment. Instead of targeting prefrontal circuits, these protocols stimulate the primary motor cortex (M1), which activates descending pain inhibition pathways.

Early results: 30-40% reductions in pain scores. Some people get meaningful relief that persists for weeks after the stimulation course ends. If you’ve been living with chronic pain and have exhausted other options, those numbers are worth paying attention to.

Substance use disorders

Beyond the FDA-cleared smoking cessation indication, TMS is being studied for methamphetamine use disorder, with an active Phase 1-2 trial testing whether theta burst stimulation affects cravings and brain activity in people who use methamphetamine. UCSF is also running a pilot study of TMS for adolescents with OCD who have had limited improvement with standard treatments.

Additional active studies

UC Berkeley is recruiting 30 subjects with MDD for a study using multimodal imaging (fMRI and EEG) to identify biomarkers that predict TMS treatment response. UC San Diego is investigating the combined effectiveness of rTMS and telehealth-based therapy for managing mild traumatic brain injury (mTBI)-related headaches. Mass General (NCT03276793) continues to recruit for TMS studies across multiple indications.

Major research institutions running TMS studies

These centers consistently run the most significant TMS clinical trials. Good starting points if you’re looking for a study:

Stanford University — Pioneered the accelerated SAINT protocol and keeps pushing the boundaries of TMS targeting and scheduling. Currently running trials for depression, anxiety, and substance use disorders.

Columbia University — Strong PTSD and depression programs with deep expertise in deep TMS and combined TMS-psychotherapy approaches.

Medical University of South Carolina (MUSC) — One of the original TMS research centers in the U.S. Ongoing trials across multiple indications including bipolar depression and smoking cessation.

UCLA Semel Institute — Active chronic pain, autism, and substance use disorder programs. Also studying TMS-EEG biomarkers to predict treatment response.

Massachusetts General Hospital / Harvard — Bipolar depression, OCD augmentation, and adolescent depression trials. Known for rigorous trial design and large sample sizes.

You can find TMS specialists at these institutions through our provider directory. Many of them treat people outside of clinical trials too.

How to find and enroll in a TMS clinical trial

ClinicalTrials.gov

Start here: ClinicalTrials.gov. Search for “transcranial magnetic stimulation” plus your condition. Filter by status (“Recruiting”) and location to find active trials near you. Each listing includes eligibility criteria, the study protocol, contact information for the research coordinator, and the study site addresses.

What to look for in a trial listing

Not all trials are equal. Prioritize studies that are:

• Randomized and sham-controlled — You get the best chance of receiving real treatment (typically 50-75% of participants get active TMS) and the most reliable data.
• Multi-site — Larger studies with multiple locations tend to be better funded, better organized, and more likely to produce meaningful results.
• Phase II or Phase III — Earlier phase studies are more exploratory. Phase II and III trials have already shown enough promise to justify larger investment.

What participation involves

A typical TMS clinical trial looks like this:

1. Screening (1-2 visits) — Psychiatric evaluation, medical history review, and often a brain MRI. Some studies require a washout period from current medications.
2. Treatment phase (4-6 weeks) — Daily TMS sessions, usually 20-30 treatments. You’ll complete mood and symptom rating scales at each visit.
3. Follow-up (3-12 months) — Periodic check-ins to track how long your response lasts. Some studies offer open-label treatment extensions if you responded.

Most trials cover all treatment costs. Many pay you for travel and time — typically $25-75 per visit. You’ll need to commit to the full schedule. Missing sessions can disqualify you from the study and compromise the research.

Who qualifies

Eligibility criteria vary, but most TMS trials require:

• A confirmed diagnosis of the target condition
• Documented treatment resistance (usually 1-2 failed adequate medication trials)
• No history of seizures or metallic implants in the head
• Age 18-70 (some studies include adolescents)
• Stable on current medications for 4-6 weeks
• No active substance use disorders (unless that’s the study target)

The bigger picture

Every TMS clinical trial brings the field closer to new FDA clearances. That means insurance coverage, wider availability, and better protocols for conditions that currently have limited treatment options.

Participating in a trial doesn’t just get you access to treatment. It adds to evidence that could help millions of people down the line.

If you’re considering TMS for any condition, check whether there’s an active trial in your area. Browse our treatment guides for the latest evidence on specific conditions, or find a TMS provider near you who can talk to you about whether a clinical trial makes sense for your situation.

Frequently Asked Questions

How do I find active TMS clinical trials near me?

The best starting point is ClinicalTrials.gov — search for “transcranial magnetic stimulation” plus your condition and filter by recruiting status and location. You can also contact research centers directly (Stanford, Columbia, MUSC, UCLA, Mass General all run TMS trials regularly) and ask their coordinators about upcoming studies. Our provider directory includes academic medical centers that frequently participate in TMS research.

Are TMS clinical trials free to participate in?

Most trials cover all treatment costs — that’s one of the main incentives for participation. Many also pay for travel and time (typically $25–75 per visit). However, you typically need to cover your own diagnostic evaluations if they exceed the study’s screening requirements, and participation doesn’t guarantee you’ll receive active treatment (sham-controlled trials mean some participants get inactive treatment).

What is a sham TMS control and why do trials use it?

Sham TMS mimics the treatment experience without delivering actual magnetic stimulation — a sham coil looks and sounds like the real thing but produces no measurable effect on brain activity. Trials use sham controls because TMS has a strong placebo response; without a sham group, it’s impossible to know whether improvements came from the stimulation itself or just from believing you received treatment. In most trials, 50–75% of participants receive real TMS.

Can I drop out of a clinical trial if it’s not working for me?

Yes — trial participation is always voluntary and you can withdraw at any time without penalty to your ongoing medical care. That said, most trials ask that you commit to the full schedule before enrolling, and missing sessions can disqualify you from the study and compromise the research integrity. Discuss your expectations with the research coordinator before signing up.

Do TMS clinical trials help advance the field even if the treatment doesn’t work for me?

Absolutely. Every trial participant adds to the evidence base — even negative results tell researchers what doesn’t work and why. Your participation contributes to the data that will eventually lead to new FDA clearances, insurance coverage expansion, and better protocols for conditions that currently have limited treatment options.